Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
목요일, 9월 03

Teva Pharmaceutical Industries Ltd

TEVANYSE
Trade with Public
Trade with Public
$37.49
1.303.59%
가까이에: Sep 2, 5:00 PM EST
$37.55
0.0550.15%
시간외: 7:25 PM EST
PRO
변동 이유?:Teva Pharmaceutical Industries shares are trading higher after the company ...
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Teva Pharmaceutical Indus Financials

Teva Pharmaceutical Indus (TEVA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Teva's Innovative Drug Portfolio Fuels Growth as Company Raises Outlook, Transitions to Direct NYSE Listing

Teva revenue tops estimates despite an earnings miss. The company raises 2026 sales guidance and highlights strong brand growth.
Vandana Singh

PRO
Teva Pharmaceutical Indus Lowers FY2026 Adj EPS Guidance from $2.57-$2.77 to $1.91-$2.11 vs $2.04 Est; Raises FY2026 Sales Guidance from $16.400B-$16.800B to $16.500B-$16.850B vs $16.618B Est

Teva Pharmaceutical Indus (NYSE:TEVA) lowers FY2026 Adj EPS guidance from $2.57-$2.77 to $1.91-$2.11 vs $2.04 analyst estimate. Raises FY2026 sales outlook from $16.400 billion-$16.800 billion to $16.500 billion-$16.850
Benzinga Newsdesk

PRO
Teva Pharmaceutical Indus Q2 Adj. EPS $0.02 Misses $0.25 Estimate, Sales $4.142B Beat $4.047B Estimate

Teva Pharmaceutical Indus (NYSE:TEVA) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.25 by 92 percent. This is a 96.97 percent decrease over earnings of $0.66 per share
Benzinga Newsdesk

Teva Signals Confidence With $700 Million Pipeline Push, Buyback Plan

Teva to acquire Emalex for $700 million, posts Q1 earnings beat, and maintains 2026 outlook amid margin and buyback plans.
Vandana Singh

Earnings Scheduled For April 29, 2026

Benzinga Insights

PRO
Teva Pharmaceutical Indus Affirms FY2026 Adj EPS Guidance of $2.57-$2.77 vs $2.67 Est; Affirms FY2026 Sales Guidance of $16.400B-$16.800B vs $16.570B Est

Teva Pharmaceutical Indus (NYSE:TEVA) affirms FY2026 Adj EPS guidance from $2.57-$2.77 to $2.57-$2.77 vs $2.67 analyst estimate. Affirms FY2026 sales outlook from $16.400 billion-$16.800 billion to $16.400
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved